Genenta Science S.p.A.
GNTADrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pembrolizumab | Phase 2 | Clear Cell RCC | - | - |
Temferon | Phase 2 | Glioblastoma Multiforme | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Genenta Science S.p.A.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Genenta Science S.p.A.'s (GNTA) pipeline across Phase 2. Its lead program is Pembrolizumab (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Genenta Science S.p.A.'s next FDA catalyst?→
Genenta Science S.p.A.'s (GNTA) next tracked catalyst is a Phase 2 expected September 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GNTA biotech catalysts?→
Add GNTA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Genenta Science S.p.A.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.